Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Targeted Oncology · 2024
DOI: 10.1007/s11523-024-01069-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Targeted Oncology, 2024. Verfasst von Maki Yoshino und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Glucocorticoids, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
BACKGROUND: The impact of glucocorticoid administration for adverse events (AEs), including immune-related AEs, on the effectiveness of immune checkpoint inhibitor (ICI) combination therapy for advanced renal cell carcinoma (RCC) remains unknown. OBJECTIVES: To clarify the prognostic impact of glucocorticoid use for AEs during first-line ICI combination therapy for advanced RCC. PATIENTS AND METHODS: We retrospectively evaluated data from 194 patients who received dual ICI combination therapy [i.e., immunotherapy (IO)-IO] or combinations of ICIs with tyrosine kinase inhibitors (TKIs) as first-line therapy. The patients were divided into two groups according to the history of glucocorticoid administration in each treatment group. Survival based on glucocorticoid administration was assessed. RESULTS: A total of 101 (52.0%) and 93 (48.0%) patients received IO-IO and IO-TKI combination therapy, respectively. Glucocorticoids were administered to 46 (46%) and 22 (24%) patients in the IO-IO and IO-TKI groups, respectively. In the IO-IO group, progression-free survival (PFS) and overall survival (OS) were significantly longer in patients with glucocorticoid administration than in those without administration (median PFS: 14.4 versus 3.45 months, p = 0.0005; median OS: 77.6 versus 33.9 months, p = 0.0025). Multivariable analysis showed that glucocorticoid administration was an independent predictor of longer PFS (hazard ratio: 0.43, p = 0.0005) and OS (hazard ratio: 0.35, p = 0.0067) after adjustment for covariates. In the IO-TKI group, neither PFS nor OS significantly differed between patients treated with and without glucocorticoid administration (PFS: p = 0.0872, OS: p = 0.216). CONCLUSIONS: Glucocorticoid administration did not negatively impact the effectiveness of ICI combination therapy for RCC, prompting glucocorticoid treatment use when AEs develop.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan.
- Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan. ishihara.hiroki@twmu.ac.jp.
- Department of Urology, Joban Hospital, 57 Kaminodai, Jobankamiyunagayamachi, Iwaki, Fukushima, Japan.
- Department of Urology, Saiseikai Kazo Hospital, 1680 Kamitakayanagi, Kazo, Saitama, Japan.
- Department of Urology, Saiseikai Kawaguchi General Hospital, 5-11-5 Nishikawaguchi, Kawaguchi, Saitama, Japan.
- Department of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kouhoku, Adachi-ku, Tokyo, Japan.
ORCID-Profile: Hiroki Ishihara
Zitieren
APA
Yoshino, M., Ishihara, H., Nemoto, Y., Mizoguchi, S., Ikeda, T., Nakayama, T., Fukuda, H., Yoshida, K., Iizuka, J., Shimmura, H., Hashimoto, Y., Kondo, T., & Takagi, T. (2024). Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma. Targeted Oncology. https://doi.org/10.1007/s11523-024-01069-6
Vancouver
Yoshino M, Ishihara H, Nemoto Y, Mizoguchi S, Ikeda T, Nakayama T, et al. Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma. Targeted Oncology. 2024. doi:10.1007/s11523-024-01069-6
BibTeX
@article{Yoshino2024,
author = {Yoshino, Maki and Ishihara, Hiroki and Nemoto, Yuki and Mizoguchi, Shinsuke and Ikeda, Takashi and Nakayama, Takayuki and Fukuda, Hironori and Yoshida, Kazuhiko and Iizuka, Junpei and Shimmura, Hiroaki and Hashimoto, Yasunobu and Kondo, Tsunenori and Takagi, Toshio},
title = {Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma},
journal = {Targeted Oncology},
year = {2024},
doi = {10.1007/s11523-024-01069-6}
}
EUVIMED